• 1
    McGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001; 116: 13643.
  • 2
    Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 74755.
  • 3
    Levy Y, Sherer Y, Langevitz P, Lorber M, Rotman P, Fabrizzi F, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin: a preliminary report. Clin Rheumatol 2000; 19: 20711.
  • 4
    Sgonc R. The vascular perspective of systemic sclerosis: of chicken, mice and men. Allergy Immunol 1999; 120: 16976.
  • 5
    Sempowski GD, Beckmann MP, Derdak S, Phipps RP. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors in enhancing fibroblasts proliferation and collagen synthesis. J Immunol 1994; 152: 360614.
  • 6
    Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104: 1020.
  • 7
    Campbell DE, Georgiou GM, Kemp AS. Pooled human immunoglobulin inhibits IL-4 but not IFN-gamma or TNF-alpha secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen. Cytokine 1999; 11: 35965.
  • 8
    Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000; 94: 99104.
  • 9
    Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 2001; 104: 8603.
  • 10
    Damas JK, Gullestad L, Aass H, Simonsen S, Fjeld JG, Wikeby L, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure: modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001; 138: 18793.
  • 11
    Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001; 62: 1337.